MX2020007817A - Prevención y tratamiento del trastorno del sueño. - Google Patents
Prevención y tratamiento del trastorno del sueño.Info
- Publication number
- MX2020007817A MX2020007817A MX2020007817A MX2020007817A MX2020007817A MX 2020007817 A MX2020007817 A MX 2020007817A MX 2020007817 A MX2020007817 A MX 2020007817A MX 2020007817 A MX2020007817 A MX 2020007817A MX 2020007817 A MX2020007817 A MX 2020007817A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- sleep disorder
- disorder treatment
- compound
- formula
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title 1
- 208000019116 sleep disease Diseases 0.000 title 1
- 208000020685 sleep-wake disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Abstract
La descripción se relaciona con métodos para tratar o prevenir un trastorno de insomnio mediante la administración a un ser humano que lo necesita un compuesto de fórmula (I), o un compuesto de fórmula (IA), (IB) o (IC), o un solvato de estos, en una dosis diaria de alrededor de 0.5 mg a alrededor de 6.0 mg. En determinadas modalidades, dichos compuestos tratan o previenen eficazmente un trastorno de insomnio en el animal, mientras que producen efectos secundarios reducidos en comparación con compuestos previamente disponibles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862621290P | 2018-01-24 | 2018-01-24 | |
PCT/IB2019/050522 WO2019145850A1 (en) | 2018-01-24 | 2019-01-22 | Sleep disorder treatment and prevention |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007817A true MX2020007817A (es) | 2020-09-25 |
Family
ID=65576390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007817A MX2020007817A (es) | 2018-01-24 | 2019-01-22 | Prevención y tratamiento del trastorno del sueño. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11576913B2 (es) |
EP (1) | EP3743049A1 (es) |
JP (1) | JP7108041B2 (es) |
KR (2) | KR20230149877A (es) |
CN (1) | CN111601591A (es) |
AR (1) | AR114306A1 (es) |
AU (2) | AU2019212435B2 (es) |
CA (1) | CA3084035C (es) |
IL (1) | IL275875A (es) |
MX (1) | MX2020007817A (es) |
TW (1) | TWI759579B (es) |
WO (1) | WO2019145850A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022276010A1 (en) * | 2021-05-21 | 2024-01-18 | Purdue Pharma L.P. | Methods of treating interstitial cystitis/bladder pain syndrome |
WO2023250190A1 (en) * | 2022-06-24 | 2023-12-28 | Purdue Pharma L.P. | Methods of treating or preventing overactive bladder syndrome |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE69635048T2 (de) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
US6572891B1 (en) | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
DK1491212T3 (da) | 2002-03-29 | 2012-10-29 | Mitsubishi Tanabe Pharma Corp | Middel til behandling af søvnforstyrrelser |
US7749533B2 (en) | 2003-05-07 | 2010-07-06 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
WO2006025267A1 (ja) | 2004-08-31 | 2006-03-09 | Mitsubishi Pharma Corporation | Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬 |
WO2008033024A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
EP3564240B1 (en) | 2007-08-31 | 2022-04-06 | Purdue Pharma L.P. | Piperidine intermediates |
WO2009113703A2 (en) | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
AU2009275218C1 (en) | 2008-07-21 | 2015-02-05 | Purdue Pharma L.P. | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the uses thereof |
US10118927B2 (en) | 2012-12-27 | 2018-11-06 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
WO2014102592A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof |
JOP20190008A1 (ar) * | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
-
2019
- 2019-01-22 MX MX2020007817A patent/MX2020007817A/es unknown
- 2019-01-22 JP JP2020540342A patent/JP7108041B2/ja active Active
- 2019-01-22 CN CN201980007853.9A patent/CN111601591A/zh active Pending
- 2019-01-22 KR KR1020237035812A patent/KR20230149877A/ko not_active Application Discontinuation
- 2019-01-22 CA CA3084035A patent/CA3084035C/en active Active
- 2019-01-22 AU AU2019212435A patent/AU2019212435B2/en active Active
- 2019-01-22 US US16/964,174 patent/US11576913B2/en active Active
- 2019-01-22 EP EP19707874.4A patent/EP3743049A1/en active Pending
- 2019-01-22 WO PCT/IB2019/050522 patent/WO2019145850A1/en unknown
- 2019-01-22 KR KR1020207020996A patent/KR20200103045A/ko active Application Filing
- 2019-01-24 AR ARP190100157A patent/AR114306A1/es unknown
- 2019-01-24 TW TW108102716A patent/TWI759579B/zh active
-
2020
- 2020-07-06 IL IL275875A patent/IL275875A/en unknown
-
2022
- 2022-05-25 AU AU2022203536A patent/AU2022203536A1/en not_active Abandoned
-
2023
- 2023-01-10 US US18/152,399 patent/US20230293516A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200103045A (ko) | 2020-09-01 |
TW201940172A (zh) | 2019-10-16 |
AU2019212435A1 (en) | 2020-07-09 |
JP7108041B2 (ja) | 2022-07-27 |
US20230293516A1 (en) | 2023-09-21 |
AR114306A1 (es) | 2020-08-19 |
CN111601591A (zh) | 2020-08-28 |
CA3084035A1 (en) | 2019-08-01 |
WO2019145850A1 (en) | 2019-08-01 |
TWI759579B (zh) | 2022-04-01 |
AU2022203536A1 (en) | 2022-06-16 |
US20200345726A1 (en) | 2020-11-05 |
KR20230149877A (ko) | 2023-10-27 |
EP3743049A1 (en) | 2020-12-02 |
US11576913B2 (en) | 2023-02-14 |
IL275875A (en) | 2020-08-31 |
CA3084035C (en) | 2023-10-24 |
AU2019212435B2 (en) | 2022-03-10 |
JP2021511338A (ja) | 2021-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
MX2018007823A (es) | Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal. | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2016009231A (es) | Administracion de tasimelteon en condiciones de ayuno. | |
MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
MX2020002889A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo. | |
MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2019004200A (es) | Terapia de combinacion. | |
MX2021015390A (es) | Tratamiento para sinucleinopatias. | |
MX2022000729A (es) | Terapia de combinacion para el tratamiento del cancer. | |
MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. |